Ali Johnson1, Leanne Shulman2, Jennifer Kachajian2, Brian L Sprague2, Farrah Khan2, Ted James2, David Cranmer2, Peter Young2, Ruth Heimann2. 1. Vermont Department of Health; University of Vermont Medical Center; University of Vermont Cancer Center, Burlington; and Vermonters Taking Action Against Cancer, Williston, VT alison.johnson@vermont.gov. 2. Vermont Department of Health; University of Vermont Medical Center; University of Vermont Cancer Center, Burlington; and Vermonters Taking Action Against Cancer, Williston, VT.
Abstract
PURPOSE: In the rural United States, there are multiple potential barriers to the timely initiation of chemotherapy. The goal of this study was to identify factors associated with delays in the time from initial diagnosis to first systemic therapy (TTC) among women with breast cancer in Vermont. METHODS: Using data from the Vermont Cancer Registry, we explored TTC for 702 female Vermont residents diagnosed with stage I to III breast cancer between 2006 and 2010 who received adjuvant chemotherapy. Multivariable linear regression was used to evaluate the associations between TTC and patient, tumor, treatment, and geographic variables. RESULTS: Mean TTC was 10.2 weeks. Longer drive time (P < .001), more invasive surgery (P = .01), and breast reconstruction (P < .001) were each associated with longer TTC. Each additional 15 minutes of drive time was associated with a 0.34-week (95% CI, 0.22 to 0.46 weeks) increase in TTC. Participants age younger than 65 years whose primary payer was Medicare (n = 27) had significantly longer average TTC, by 2.37 weeks (P = .001), compared with those with private or military insurance. There was also substantial variation in TTC across hospitals (P < .001). CONCLUSION: Most female patients with stage I to III breast cancer in Vermont are receiving adjuvant chemotherapy within the National Comprehensive Cancer Network-recommended timeframe; however, improvements remain needed for certain subgroups. Novel approaches for women with long drive times need to be developed and evaluated in the community. Variation in TTC by hospital, even after adjusting for patient, tumor, and treatment factors, also suggests opportunities for process improvement.
PURPOSE: In the rural United States, there are multiple potential barriers to the timely initiation of chemotherapy. The goal of this study was to identify factors associated with delays in the time from initial diagnosis to first systemic therapy (TTC) among women with breast cancer in Vermont. METHODS: Using data from the Vermont Cancer Registry, we explored TTC for 702 female Vermont residents diagnosed with stage I to III breast cancer between 2006 and 2010 who received adjuvant chemotherapy. Multivariable linear regression was used to evaluate the associations between TTC and patient, tumor, treatment, and geographic variables. RESULTS: Mean TTC was 10.2 weeks. Longer drive time (P < .001), more invasive surgery (P = .01), and breast reconstruction (P < .001) were each associated with longer TTC. Each additional 15 minutes of drive time was associated with a 0.34-week (95% CI, 0.22 to 0.46 weeks) increase in TTC. Participants age younger than 65 years whose primary payer was Medicare (n = 27) had significantly longer average TTC, by 2.37 weeks (P = .001), compared with those with private or military insurance. There was also substantial variation in TTC across hospitals (P < .001). CONCLUSION: Most female patients with stage I to III breast cancer in Vermont are receiving adjuvant chemotherapy within the National Comprehensive Cancer Network-recommended timeframe; however, improvements remain needed for certain subgroups. Novel approaches for women with long drive times need to be developed and evaluated in the community. Variation in TTC by hospital, even after adjusting for patient, tumor, and treatment factors, also suggests opportunities for process improvement.
Authors: M Colleoni; M Bonetti; A S Coates; M Castiglione-Gertsch; R D Gelber; K Price; C M Rudenstam; J Lindtner; J Collins; B Thürlimann; S Holmberg; A Veronesi; G Marini; A Goldhirsch Journal: J Clin Oncol Date: 2000-02 Impact factor: 44.544
Authors: John M McLaughlin; Roger T Anderson; Amy K Ferketich; Eric E Seiber; Rajesh Balkrishnan; Electra D Paskett Journal: J Clin Oncol Date: 2012-11-19 Impact factor: 44.544
Authors: Dawn L Hershman; Xiaoyan Wang; Russell McBride; Judith S Jacobson; Victor R Grann; Alfred I Neugut Journal: Breast Cancer Res Treat Date: 2006-04-01 Impact factor: 4.872
Authors: Mariana Chavez-MacGregor; Christina A Clarke; Daphne Y Lichtensztajn; Sharon H Giordano Journal: JAMA Oncol Date: 2016-03 Impact factor: 31.777
Authors: Debora de Melo Gagliato; Ana M Gonzalez-Angulo; Xiudong Lei; Richard L Theriault; Sharon H Giordano; Vicente Valero; Gabriel N Hortobagyi; Mariana Chavez-Macgregor Journal: J Clin Oncol Date: 2014-01-27 Impact factor: 44.544
Authors: Jonathan L Vandergrift; Joyce C Niland; Richard L Theriault; Stephen B Edge; Yu-Ning Wong; Loretta S Loftus; Tara M Breslin; Clifford A Hudis; Sara H Javid; Hope S Rugo; Samuel M Silver; Eva M Lepisto; Jane C Weeks Journal: J Natl Cancer Inst Date: 2012-12-21 Impact factor: 13.506
Authors: Alexandra Thomas; Anthony Rhoads; Elizabeth Pinkerton; Mary C Schroeder; Kristin M Conway; William G Hundley; Lacey R McNally; Jacob Oleson; Charles F Lynch; Paul A Romitti Journal: JNCI Cancer Spectr Date: 2019-06-07
Authors: Brian L Sprague; Thomas P Ahern; Sally D Herschorn; Michelle Sowden; Donald L Weaver; Marie E Wood Journal: Prev Med Date: 2021-07-22 Impact factor: 4.018